Researchers Report New Findings on Metastatic Castration-Resistant Prostate Cancer Treatment Resistance

Researchers Report New Findings on Metastatic Castration-Resistant Prostate Cancer Treatment Resistance
A recent study on metastatic castration-resistant prostate cancer (mCRPC) showed that androgen receptor V7 (or AR-V7) status has no significant impact on the response to taxane chemotherapy. The study entitled “AR splice variant 7 (AR-V7) and response to taxanes in men with metastatic castration-resistant prostate cancer (mCRPC)” was presented during the 2015 Genitourinary Cancers Symposium held last February in Orlando by lead author Dr. Emmanuel S. Antonarakis from the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, MD. Dr. Antonarakis explained in a news release that clinicians urgently need biomarkers to decide which therapies will be effective at the individual level in advanced prostate cancer patients. Dr. Antonarakis said that testing for AR-V7 could become a very useful method to manage therapy decisions for men with hormone-resistant disease. The truncated form (AR-V7) of the androgen receptor (AR) i.e. that lacks the ligand-binding domain but always remains active, is found in a third of patients with castration-resistant prostate cancer. Recently in a clinical study, Dr. Antonarakis and colleagues demonstrated that men with mCRPC had AR-V7 in circulating tumor cells and were resistant to androgen receptor targeting drugs enzalutamide and abiraterone. Moreover, previous studies performed in experimental models of prostate cancer have also shown an association between AR-V7 and resistance to taxane chemotherapy. This study hypothesized that AR-V7[+] mCRPC patients would still have some level of sensitivity to taxane chemotherapy (docetaxel or cabazitaxel) as an initial treatment, even though they were resistant to hormone therapy. The team analyzed AR-V7 status through an experimental blood test that quantifies
Subscribe or to access all post and page content.